Endometrial hyperplasia as a risk factor of endometrial cancer.
Level 1 - systematic review of randomized trials
Systematic review searching PubMed and Cochrane Controlled Trials for progestin efficacy in endometrial hyperplasia
PubMed 35001185 · doi:10.1007/s00404-021-06380-5
What was done
The authors conducted a review of risk factors and clinical management of endometrial hyperplasia, alongside a systematic literature search across PubMed and the Cochrane Controlled Trials register to evaluate studies analyzing the efficacy of progestin treatment in women with endometrial hyperplasia.
What was found
The abstract reports no numerical data, effect sizes, sample sizes, or statistical values. It states qualitatively that chronic exposure to unopposed estrogen is the primary risk factor and that multiple studies support the efficacy of progestins in treating both benign and atypical endometrial hyperplasia.
Why it matters
Endometrial hyperplasia is the primary precursor lesion to endometrioid endometrial cancer. Clarifying the evidence for progestin efficacy informs fertility-sparing and non-surgical management strategies.
Limits
The abstract provides no quantitative outcomes, no total number of included studies or participants, and no information on progestin regimens, adverse events, recurrence rates, or risk of bias.
Cited by
- supports Administering unopposed estrogen without progesterone in women with an intact uterus increases the risk of endometrial hyperplasia and endometrial cancer.